XOMA Corporation XOMA Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Income Not From Contract With Customer Cost Recovery Method by Product | |||||
| Dsuvia | $28K— | —— | —— | —— | |
| Tovorafenib | $13.72M+328% | $3.2M— | —— | —— | |
| Revenue by Geography | |||||
| AU | $1M— | —— | —— | —— | |
| CH | $23.96M+61.9% | $14.8M— | —— | —— | |
| US | $23.09M+91.4% | $12.06M+230% | $3.66M-18.3% | $4.48M+71.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does XOMA Corporation break its business down?
- XOMA Corporation (XOMA) reports income not from contract with customer cost recovery method by product across 2 parts — Dsuvia and Tovorafenib. Each is extracted from the segment footnotes and tracked over time.
- Where does XOMA Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in XOMA Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
